Emerging innovations and advancements in the treatment of extremity and truncal soft tissue sarcomas.
extremity sarcoma
health disparities
immunotherapy
prognostics
radiotherapy
soft tissue sarcoma
surgical Innovations
Journal
Journal of surgical oncology
ISSN: 1096-9098
Titre abrégé: J Surg Oncol
Pays: United States
ID NLM: 0222643
Informations de publication
Date de publication:
27 Nov 2023
27 Nov 2023
Historique:
received:
06
11
2023
accepted:
07
11
2023
medline:
27
11
2023
pubmed:
27
11
2023
entrez:
27
11
2023
Statut:
aheadofprint
Résumé
In this special edition update on soft tissue sarcomas (STS), we cover classifications, emerging technologies, prognostic tools, radiation schemas, and treatment disparities in extremity and truncal STS. We discuss the importance of enhancing local control and reducing complications, including the role of innovative imaging, surgical guidance, and hypofractionated radiation. We review advancements in systemic and immunotherapeutic treatments and introduce disparities seen in this vulnerable population that must be considered to improve overall patient care.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Randall RL, Theriault RV, Thorpe SW, Monument MJ. Emerging innovations and advancements in the field of musculoskeletal oncology. J Surg Oncol. 2023;128(3):415-417. doi:10.1002/jso.27409
Bansal A, Goyal S, Goyal A, Jana M. WHO classification of soft tissue tumours 2020: an update and simplified approach for radiologists. Eur J Radiol 2021;143:109937. doi:10.1016/j.ejrad.2021.109937
Sbaraglia M, Bellan E, Dei Tos AP. The 2020 WHO classification of soft tissue tumours: news and perspectives. Pathologica. 2021;113(2):70-84. doi:10.32074/1591-951X-213
Crombé A, Spinnato P, Italiano A, et al. Radiomics and artificial intelligence for soft-tissue sarcomas: current status and perspectives. Diag Interv Imaging. 2023:S2211-5684(23)00179-1. doi:10.1016/j.diii.2023.09.005
Arthur A, Johnston EW, Winfield JM, et al. Virtual biopsy in soft tissue sarcoma. How close are we? Front Oncol. 2022;12:892620. doi:10.3389/fonc.2022.892620
Fanciullo C, Gitto S, Carlicchi E, Albano D, Messina C, Sconfienza LM. Radiomics of musculoskeletal sarcomas: a narrative review. J Imaging. 2022;8(2):45. doi:10.3390/jimaging8020045
Malinauskaite I, Hofmeister J, Burgermeister S, et al. Radiomics and machine learning differentiate soft-tissue lipoma and liposarcoma better than musculoskeletal radiologists. Sarcoma. 2020;2020:1-9. doi:10.1155/2020/7163453
Xu W, Hao D, Hou F, Zhang D, Wang H. Soft tissue sarcoma: preoperative MRI-based radiomics and machine learning may be accurate predictors of histopathologic grade. Am J Roentgenol. 2020;215(4):963-969. doi:10.2214/AJR.19.22147
Frankel AO, Lathara M, Shaw CY, et al. Machine learning for rhabdomyosarcoma histopathology. Mod Pathol. 2022;35(9):1193-1203. doi:10.1038/s41379-022-01075-x
Foersch S, Eckstein M, Wagner DC, et al. Deep learning for diagnosis and survival prediction in soft tissue sarcoma. Ann Oncol. 2021;32(9):1178-1187. doi:10.1016/j.annonc.2021.06.007
Koelsche C, Schrimpf D, Stichel D, et al. Sarcoma classification by DNA methylation profiling. Nat Commun. 2021;12(1):498. doi:10.1038/s41467-020-20603-4
Kaiser D, Hoch A, Kriechling P, et al. The influence of different patient positions on the preoperative 3D planning for surgical resection of soft tissue sarcoma in the lower limb-a cadaver pilot study. Surg Oncol. 2020;35:478-483. doi:10.1016/j.suronc.2020.10.008
Moreta-Martinez R, García-Mato D, García-Sevilla M, Pérez-Mañanes R, Calvo-Haro JA, Pascau J. Combining augmented reality and 3D printing to display patient models on a smartphone. J Vis Exp. 2020;155(155). doi:10.3791/60618
Ozturk AM, Sirinturk S, Kucuk L, et al. Multidisciplinary assessment of planning and resection of complex bone tumor using patient-specific 3D model. Indian J Surg Oncol. 2019;10(1):115-124. doi:10.1007/s13193-018-0852-5
Heunis JC, Cheah JW, Sabnis AJ, Wustrack RL. Use of three-dimensional printing and intraoperative navigation in the surgical resection of metastatic acetabular osteosarcoma. BMJ Case Rep. 2019;12(9):e230238. doi:10.1136/bcr-2019-230238
Abdel Al S, Chaar MKA, Mustafa A, Al-Hussaini M, Barakat F, Asha W. Innovative surgical planning in resecting soft tissue sarcoma of the foot using augmented reality with a smartphone. J Foot Ankle Surg. 2020;59(5):1092-1097. doi:10.1053/j.jfas.2020.03.011
McCulloch RA, Frisoni T, Kurunskal V, Maria Donati D, Jeys L. Computer navigation and 3D printing in the surgical management of bone sarcoma. Cells. 2021;10(2):195. doi:10.3390/cells10020195
Nicoli F, Saleh DB, Baljer B, et al. Intraoperative near-infrared fluorescence (NIR) imaging with indocyanine green (ICG) can identify bone and soft tissue sarcomas which may provide guidance for oncological resection. Ann Surg. 2021;273(2):e63-e68. doi:10.1097/SLA.0000000000003857
Brookes MJ, Chan CD, Nicoli F, et al. Intraoperative near-infrared fluorescence guided surgery using indocyanine green (ICG) for the resection of sarcomas may reduce the positive margin rate: an extended case series. Cancers. 2021;13(24):6284. doi:10.3390/cancers13246284
Gong MF, Li WT, Bhogal S, et al. Intraoperative evaluation of soft tissue sarcoma surgical margins with indocyanine Green fluorescence imaging. Cancers. 2023;15(3):582. doi:10.3390/cancers15030582
Hadjipanayis CG, Stummer W. 5-ALA and FDA approval for glioma surgery. JNO 2019;141(3):479-486. doi:10.1007/s11060-019-03098-y
Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F. Reulen H-J. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006;7(5):392-401. doi:10.1016/S1470-2045(06)70665-9
Stummer W, Tonn JC, Mehdorn HM, et al. Counterbalancing risks and gains from extended resections in malignant glioma surgery: a supplemental analysis from the randomized 5-aminolevulinic acid glioma resection study. J Neurosurg. 2011;114(3):613-623. doi:10.3171/2010.3.JNS097
Guder WK, Hartmann W, Buhles C, et al. 5-ALA-mediated fluorescence of musculoskeletal tumors in a chick chorio-allantoic membrane model: preclinical in vivo qualification analysis as a fluorescence-guided surgery agent in orthopedic oncology. J Orthop Surg Res. 2022;17(1):34. doi:10.1186/s13018-022-02931-x
Kenan S, Liang H, Goodman HJ, et al. 5-Aminolevulinic acid tumor paint and photodynamic therapy for myxofibrosarcoma: an in vitro study. J Orthop Surg Res. 2020;15(1):94. doi:10.1186/s13018-020-01606-9
Sachsenmaier SM, Walter C, Liang C, Riester R, Wülker N, Danalache M. 5-aminolevulinic acid-mediated photodynamic therapy on primary bone tumor and bone metastases cell lines. J Visualized Exp. 2022;183:63644. doi:10.3791/63644
Jang WY, Kim HS, Han I. Impact of surgical margin on survival in extremity soft tissue sarcoma: a systematic review and meta-analysis. Medicine. 2021;100(3):e24124. doi:10.1097/MD.0000000000024124
Gouin F, Stoeckle E, Honoré C, et al. Overall survival in patients with re-excision of positive microscopic margins of limb and trunk wall soft tissue sarcoma operated outside of a reference center: a nationwide cohort analysis. BMC Cancer. 2022;22(1):1034. doi:10.1186/s12885-022-10121-5
Stauss R, Aigner A, Richter A, et al. The prognostic significance of surgical resection margins for local recurrence, distant metastasis, and overall survival in sarcoma. J Surg Oncol. 2023;128(7):1160-1170. doi:10.1002/jso.27411
Traub F, Griffin AM, Wunder JS, Ferguson PC. Influence of unplanned excisions on the outcomes of patients with stage III extremity soft-tissue sarcoma. Cancer. 2018;124(19):3868-3875. doi:10.1002/cncr.31648
Gundle KR, Kafchinski L, Gupta S, et al. Analysis of margin classification systems for assessing the risk of local recurrence after soft tissue sarcoma resection. J Clin Oncol. 2018;36(7):704-709. doi:10.1200/JCO.2017.74.6941
Liang Y, Guo T, Hong D, Xiao W, Zhou Z, Zhang X. Time to local recurrence as a predictor of survival in patients with soft tissue sarcoma of the extremity and abdominothoracic wall. Front Oncol. 2020;10:599097. doi:10.3389/fonc.2020.599097
Frobert P, Vaucher R, Vaz G, Gouin F, Meeus P, Delay E. The role of reconstructive surgery after soft tissue sarcoma resection. Ann Chirurgie Plast Esthétique. 2020;65(5-6):394-422. doi:10.1016/j.anplas.2020.05.009
Hasegawa H, Tsukamoto S, Honoki K, et al. Soft-tissue reconstruction after soft-tissue sarcoma resection: the clinical outcomes of 24 patients. Eur J Orthop Surg Traumatol. 2022;32(1):1-10. doi:10.1007/s00590-021-02901-9
Lucattelli E, Lusetti IL, Cipriani F, Innocenti A, De Santis G, Innocenti M. Reconstruction of upper limb soft-tissue defects after sarcoma resection with free flaps: a systematic review. J Plast Reconst Aest Surg. 2021;74(4):755-767. doi:10.1016/j.bjps.2020.10.065
Parikh RP, Sacks JM. Lower extremity reconstruction after soft tissue sarcoma resection. Clin Plast Surg. 2021;48(2):307-319. doi:10.1016/j.cps.2021.01.007
Aten DM, Chang EI. Practical strategies in reconstruction of soft-tissue sarcoma. Plast Reconstr Surg. 2022;150(5):1082e-1094e. doi:10.1097/PRS.0000000000009604
Simman R. Wound closure and the reconstructive ladder in plastic surgery. J Am Col Certif Wound Spec. 2009;1(1):6-11. doi:10.1016/j.jcws.2008.10.003
Sparber-Sauer M, Ferrari A, Spunt SL, et al. The significance of margins in pediatric non-rhabdomyosarcoma soft tissue sarcomas: consensus on surgical margin definition harmonization from the INternational Soft Tissue SaRcoma ConsorTium (INSTRuCT). Cancer Med. 2023;12(10):11719-11730. doi:10.1002/cam4.5671
Gonzalez MR, Clunk MJ, Bedi ADS, et al. Prognostic and predictive factors in undifferentiated pleomorphic sarcoma: a long-term study from a large tertiary care urban center. J Surg Oncol. 2023;128(2):322-331. doi:10.1002/jso.27279
Houdek MT, Beahrs TR, Wyles CC, Rose PS, Sim FH, Turner NS. What factors are predictive of outcome in the treatment of soft tissue sarcomas of the foot and ankle? Foot Ankle Special. 2017;10(1):12-19. doi:10.1177/1938640016666925
Iqbal N, Shukla NK, Deo SVS, et al. Prognostic factors affecting survival in metastatic soft tissue sarcoma: an analysis of 110 patients. Clin Transl Oncol. 2016;18(3):310-316. doi:10.1007/s12094-015-1369-9
Phan EN, Thorpe SW, Wong FS, et al. Opportunistic muscle measurements on staging chest CT for extremity and truncal soft tissue sarcoma are associated with survival. J Surg Oncol. 2020;122(5):869-876. doi:10.1002/jso.26077
Winchester D, Lehman J, Tello T, et al. Undifferentiated pleomorphic sarcoma: factors predictive of adverse outcomes. J Am Acad Dermatol. 2018;79(5):853-859. doi:10.1016/j.jaad.2018.05.022
Mariani L, Miceli R, Kattan MW, et al. Validation and adaptation of a nomogram for predicting the survival of patients with extremity soft tissue sarcoma using a three-grade system. Cancer. 2005;103:402-408. doi:10.1002/cncr.20778
Cahlon O, Brennan MF, Jia X, Qin LX, Singer S, Alektiar KM. A postoperative nomogram for local recurrence risk in extremity soft tissue sarcomas after limb-sparing surgery without adjuvant radiation. Ann Surg. 2012;255:343-347. doi:10.1097/SLA.0b013e3182367aa7
Callegaro D, Miceli R, Bonvalot S, et al. Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis. Lancet Oncol. 2016;17:671-680. doi:10.1016/S1470-2045(16)00010-3
Rueten-Budde AJ, van Praag VM, Fiocco M, et al. Dynamic prediction of overall survival for patients with high-grade extremity soft tissue sarcoma. Surg Oncol. 2018;27:695-701. doi:10.1016/j.suronc.2018.09.003
Callegaro D, Miceli R, Bonvalot S, et al. Development and external validation of a dynamic prognostic nomogram for primary extremity soft tissue sarcoma survivors. Eclinicalmedicine. 2019;17:100215. doi:10.1016/j.eclinm.2019.11.008
Xu F, Zhao F, Feng X, et al. Nomogram for predicting cancer-specific survival in undifferentiated pleomorphic sarcoma: a surveillance, epidemiology, and end results-based study. Cancer Control. 2021;28:107327482110367. doi:10.1177/10732748211036775
Smith SR, Vargo M, Zucker DS, et al. The cancer rehabilitation Medicine metrics consortium: a path to enhanced, multi-site outcome assessment to enhance care and demonstrate value. Front Oncol. 2021;10:625700. doi:10.3389/fonc.2020.625700
Smith SR, Vargo M, Zucker D, et al. Psychometric characteristics and validity of the PROMIS cancer function brief 3D profile. Arch Phys Med Rehabil. 2022;103(5S):S146-S161. doi:10.1016/j.apmr.2020.12.027
Qin ES, Richards B, Smith SR. Function in cancer patients: disease and clinical determinants. Cancers. 2023;15(13):3515. doi:10.3390/cancers15133515
Pasquali S, Palmerini E, Quagliuolo V, et al. Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: a sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial. Cancer. 2022;128(1):85-93. doi:10.1002/cncr.33895
Voss RK, Callegaro D, Chiang YJ, et al. Sarculator is a good model to predict survival in resected extremity and trunk sarcomas in US patients. Ann Surg Oncol. 2022, 29, 4376-4385. doi:10.1245/s10434-022-11442-2
Rueten-Budde AJ, van Praag VM, van de Sande MAJ, et al. Dynamic prediction of overall survival for patients with high-grade extremity soft tissue sarcoma. Surg Oncol. 2018;27(4):695-701. doi:10.1016/j.suronc.2018.09.003
Rueten-Budde AJ, van Praag VM, van de Sande MAJ, Fiocco M. External validation and adaptation of a dynamic prediction model for patients with high-grade extremity soft tissue sarcoma. J Surg Oncol. 2021;123(4):1050-1056. doi:10.1002/jso.26337
Hagenmaier HSF, van Beeck AGK, Haas RL, et al. The influence of personalised sarcoma care (PERSARC) prediction modelling on clinical decision making in a multidisciplinary setting. Sarcoma. 2021;2021:1-6. doi:10.1155/2021/8851354
Acem I, van Houdt WJ, Grünhagen DJ, et al. The role of perioperative chemotherapy in primary high-grade extremity soft tissue sarcoma: a risk-stratified analysis using PERSARC. Eur J Cancer 2022;165:71-80. doi:10.1016/j.ejca.2022.01.013
O'Donnell PW, Griffin AM, Eward WC, et al. The effect of the setting of a positive surgical margin in soft tissue sarcoma. Cancer. 2014;120(18):2866-2875. doi:10.1002/cncr.28793
O'Sullivan B, Davis AM, Turcotte R, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet 2002;359(9325):2235-2241. doi:10.1016/S0140-6736(02)09292-9
Salerno KE, Alektiar KM, Baldini EH, et al. Radiation therapy for treatment of soft tissue sarcoma in adults: executive summary of an ASTRO clinical practice guideline. Pract Radiat Oncol. 2021;11(5):339-351. doi:10.1016/j.prro.2021.04.005
Koseła-Paterczyk H, Teterycz P, Spałek M, et al. Efficacy and safety of hypofractionated preoperative radiotherapy for primary locally advanced soft tissue sarcomas of limbs or trunk wall. Cancers. 2021;13(12):2981. doi:10.3390/cancers13122981
Spałek MJ, Koseła-Paterczyk H, Borkowska A, et al. Combined preoperative hypofractionated radiotherapy with doxorubicin-ifosfamide chemotherapy in marginally resectable soft tissue sarcomas: results of a phase 2 clinical trial. Int J Radiat Oncol Biol Phys. 2021;110(4):1053-1063. doi:10.1016/j.ijrobp.2021.02.019
Leite ETT, Munhoz RR, Camargo VP, et al. Neoadjuvant stereotactic ablative radiotherapy (SABR) for soft tissue sarcomas of the extremities. Radiother Oncol. 2021;161:222-229. doi:10.1016/j.radonc.2021.06.027
Potkrajcic V, Traub F, Hermes B, et al. Hypofractionated preoperative radiotherapy for high risk soft tissue sarcomas in a geriatric patient population. Radiol Oncol. 2021;55(4):459-466. doi:10.2478/raon-2021-0038
Gobo Silva ML, Lopes de Mello CA, Aguiar Junior S, et al. Neoadjuvant hypofractionated radiotherapy and chemotherapy for extremity soft tissue sarcomas: safety, feasibility, and early oncologic outcomes of a phase 2 trial. Radiother Oncol. 2021;159:161-167. doi:10.1016/j.radonc.2021.03.033
Koseła-Paterczyk H, Spałek M, Borkowska A, et al. Hypofractionated radiotherapy in locally advanced myxoid liposarcomas of extremities or trunk wall: results of a single-arm prospective clinical trial. J Clin Med. 2020;9(8):2471. doi:10.3390/jcm9082471
Parsai S, Lawrenz J, Kilpatrick S, et al. Early outcomes of preoperative 5-fraction radiation therapy for soft tissue sarcoma followed by immediate surgical resection. Adv Radiat Oncol. 2020;5(6):1274-1279. doi:10.1016/j.adro.2020.06.024
Lansu J, Bovée JVMG, Braam P, et al. Dose reduction of preoperative radiotherapy in myxoid liposarcoma: a nonrandomized controlled trial. JAMA Oncol. 2021;7(1):e205865. doi:10.1001/jamaoncol.2020.5865
Guadagnolo BA, Bassett RL, Mitra D, et al. Hypofractionated, 3-week, preoperative radiotherapy for patients with soft tissue sarcomas (HYPORT-STS): a single-centre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2022;23(12):1547-1557. doi:10.1016/S1470-2045(22)00638-6
Barker HE, Paget JTE, Khan AA, Harrington KJ. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer 2015;15(7):409-425. doi:10.1038/nrc3958
Colton M, Cheadle EJ, Honeychurch J, Illidge TM. Reprogramming the tumour microenvironment by radiotherapy: implications for radiotherapy and immunotherapy combinations. Radiat Oncol. 2020;15(1):254. doi:10.1186/s13014-020-01678-1
Schöffski P. Established and experimental systemic treatment options for advanced liposarcoma. Oncol Res Treat. 2022;45(9):525-543. doi:10.1159/000524939
Lam SW, Silva TM, Traast-Kooistra J, et al. Histological response to radiotherapy is an early event in myxoid liposarcoma. Virchows Arch. 2023;483(4):487-495. doi:10.1007/s00428-023-03615-5
Lansu J, Braam PM, van Werkhoven E, et al. A moderate dose of preoperative radiotherapy may improve resectability in myxoid liposarcoma. Eur J Surg Oncol. 2021;47(10):2633-2639. doi:10.1016/j.ejso.2021.06.020
Houdek MT, Mallett KE, Heidenreich MJ, et al. Lack of radiosensitivity predicts poor disease specific survival in myxoid liposarcoma. J Surg Oncol. 2023;127(5):848-854. doi:10.1002/jso.27190
Snow H, Mitchell C, Hendry S, et al. Characterising the immune microenvironment in liposarcoma, its impact on prognosis and the impact of radiotherapy. J Surg Oncol. 2021;123(1):117-126. doi:10.1002/jso.26261
Minopoli M, Sarno S, Cannella L, et al. Crosstalk between macrophages and myxoid liposarcoma cells increases spreading and invasiveness of tumor cells. Cancers. 2021;13(13):3298. doi:10.3390/cancers13133298
Allignet B, Meurgey A, Bouhamama A, et al. Impact of histological subtype on radiological and pathological response after neoadjuvant radiotherapy in soft tissue sarcoma. Eur J Surg Oncol. 2021;47(12):2995-3003. doi:10.1016/j.ejso.2021.07.008
Dammerer D, Neugebauer J, Braito M, et al. Midterm results of high-dose-rate intraoperative brachytherapy in the treatment of soft tissue sarcomas. Cancers. 2023;15(10):2854. doi:10.3390/cancers15102854
Seidensaal K, Dostal M, Kudak A, et al. Preoperative dose-escalated intensity-modulated radiotherapy (IMRT) and intraoperative radiation therapy (IORT) in patients with retroperitoneal soft-tissue sarcoma: final results of a clinical phase I/II trial. Cancers. 2023;15(10):2747. doi:10.3390/cancers15102747
Willis F, Schimmack S, Uhl M, et al. Significance of intraoperative radiation therapy and high cumulative radiation doses in retroperitoneal soft tissue sarcoma. Eur J Surg Oncol. 2020;46(5):905-913. doi:10.1016/j.ejso.2019.12.014
Sarria GR, Petrova V, Wenz F, Abo-Madyan Y, Sperk E, Giordano FA. Intraoperative radiotherapy with low energy x-rays for primary and recurrent soft-tissue sarcomas. Radiat Oncol. 2020;15(1):110. doi:10.1186/s13014-020-01559-7
Roeder F, Morillo V, Saleh-Ebrahimi L, Calvo FA, Poortmans P, Ferrer Albiach C. Intraoperative radiation therapy (IORT) for soft tissue sarcoma-ESTRO IORT task force/ACROP recommendations. Radiother Oncol. 2020;150:293-302. doi:10.1016/j.radonc.2020.07.019
Sanniec KJ, Velazco CS, Bryant LA, et al. Immediate versus delayed sarcoma re- construction: impact on outcomes. Sarcoma 2016;2016:1-5.
Sanniec KJ, Swanson S, Casey 3rd WJ, Schwartz A, Bryant L, Rebecca AM. Predictive factors of wound complications after sarcoma resection requiring plastic surgeon involvement. Ann Plast Surg. 2013;71:283-285.
Nystrom LM, Mesko NW, Jin Y, et al. Transcutaneous oximetry does not reliably predict wound-healing complications in preoperatively radiated soft tissue sarcoma. Clin Orthop Rel Res. 2023;481(3):542-549. doi:10.1097/CORR.0000000000002279
Lazarides AL, Saltzman EB, Visgauss JD, Mithani SK, Eward WC, Brigman BE. Intraoperative angiography imaging correlates with wound complications following soft tissue sarcoma resection. J Orthop Res. 2022;40(10):2382-2390. doi:10.1002/jor.25270
Ramsey DC, Walker JR, Wetzel R, Gundle KR, Hayden JB, Doung YC. Is the addition of anaerobic coverage to perioperative antibiotic prophylaxis during soft tissue sarcoma resection associated with a reduction in the proportion of wound complications? Clin Orthop Rel Res. 2022;480(12):2409-2417. doi:10.1097/CORR.0000000000002308
Dadras M, Ufton D, Sogorski A, et al. Closed-incision negative-pressure wound therapy after resection of soft-tissue tumors reduces wound complications: results of a randomized trial. Plast Reconstr Surg. 2022;149(5):972e-980e. doi:10.1097/PRS.0000000000009023
Mole RH. Whole body irradiation; radiobiology or medicine? Br J Radiol. 1953;26:234-241.
Siva S, MacManus MP, Martin RF, Martin OA. Abscopal effects of radiation therapy: a clinical review for the radiobiologist. Cancer Lett. 2015;356:82-90.
Kaminski JM, Shinohara E, Summers JB, Niermann KJ, Morimoto A, Brousal J. The controversial abscopal effect. Cancer Treat Rev. 2005;31:159-172.
Oshiro Y, Mizumoto M, Hisanaga T, et al. Abscopal effect with fever of unknown cause during radiotherapy: two case reports and review of the literature. Exp Ther Med. 2023;26(5):510. doi:10.3892/etm.2023.12209
Deng L, Liang H, Burnette B, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124:687-695.
Lauber K, Dunn L. Immunotherapy mythbusters in head and neck cancer: the abscopal effect and pseudoprogression. Am Soc Clin Oncol Educ Book. 2019;39:352-363.
Grimaldi AM, Simeone E, Giannarelli D, et al. Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. Oncoimmunology. 2014;3:e28780.
Niknam S, Barsoumian HB, Schoenhals JE, et al. Radiation followed by OX40 stimulation drives local and abscopal antitumor effects in an antiPD1-resistant lung tumor model. Clin Cancer Res. 2018;24:5735-5743.
Callaghan CM, Seyedin SN, Mohiuddin IH, et al. The effect of concurrent stereotactic body radiation and anti-PD-1 therapy for recurrent metastatic sarcoma. Radiat Res. 2020;194(2):124-132. doi:10.1667/RADE-20-00017
Vanpouille-Box C, Alard A, Aryankalayil MJ, et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun. 2017;8:15618.
Tsagozis P, Gonzalez-Molina J, Georgoudaki AM, et al. Sarcoma tumor microenvironment. Adv Exp Med Biol. 2020;1296:319-348. doi:10.1007/978-3-030-59038-3_20
Tap WD, Wagner AJ, Schöffski P, et al. Effect of doxorubicin plus olaratumab vs doxorubicin plus placebo on survival in patients with advanced soft tissue sarcomas: the ANNOUNCE randomized clinical trial. JAMA. 2020;323(13):1266-1276. doi:10.1001/jama.2020.1707
Tap WD, Jones RL, Van Tine BA, et al. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet. 2016;388(10043):488-497. doi:10.1016/S0140-6736(16)30587-6
Gronchi A, Ferrari S, Quagliuolo V, et al. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol. 2017;18(6):812-822. doi:10.1016/S1470-2045(17)30334-0
Liu XX, Han YH, Kuang BH, Lin GH, Wang BC. Novel-fosfamide monotherapy or in combination with doxorubicin versus doxorubicin alone in patients with advanced soft tissue sarcoma: a pooled analysis of randomized clinical trials. Medicine. 2023;102(33):e34902. doi:10.1097/MD.0000000000034902
Wu YW, Lee DY, Lu YL, et al. Platelet extracellular vesicles are efficient delivery vehicles of doxorubicin, an anti-cancer drug: preparation and in vitro characterization. Platelets. 2023;34(1):2237134. doi:10.1080/09537104.2023.2237134
Haney MJ, Zhao Y, Jin YS, et al. Macrophage-derived extracellular vesicles as drug delivery systems for triple negative breast cancer (TNBC) therapy. J Neuroimmune Pharmacol. 2020;15(3):487-500. doi:10.1007/s11481-019-09884-9
Fazal S, Lee R. Biomimetic bacterial membrane vesicles for drug delivery applications. Pharmaceutics. 2021;13(9):1430. doi:10.3390/pharmaceutics13091430
Judson I, Radford JA, Harris M, et al. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL®/CAELYX®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma. Eur J Cancer. 2001;37(7):870-877. doi:10.1016/s0959-8049(01)00050-8
Liu X, Jiang S, Wang H, et al. Pegylated liposomal doxorubicin combined with ifosfamide for treating advanced or metastatic soft-tissue sarcoma: a prospective, single-arm phase II study. Clin Cancer Res. 2022;28(24):5280-5289. doi:10.1158/1078-0432.CCR-22-1785
Chamberlain FE, Jones RL, Chawla SP. Aldoxorubicin in soft tissue sarcomas. Fut Oncol. 2019;15(13):1429-1435. doi:10.2217/fon-2018-0922
Miao L, Ma ST, Jiang X, Zhang HH, Wang YM, Li M. Prediction of the therapeutic efficacy of epirubicin combined with ifosfamide in patients with lung metastases from soft tissue sarcoma based on contrast-enhanced CT radiomics features. BMC Med Imaging 2022;22(1):131. doi:10.1186/s12880-022-00859-6
Berclaz LM, Altendorf-Hofmann A, Dürr HR, et al. Expression patterns of TOP2A and SIRT1 are predictive of survival in patients with high-risk soft tissue sarcomas treated with a neoadjuvant anthracycline-based chemotherapy. Cancers. 2021;13(19):4877. doi:10.3390/cancers13194877
Demetri GD, von Mehren M, Jones RL, et al. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol. 2016;34(8):786-793. doi:10.1200/JCO.2015.62.4734
Patel S, von Mehren M, Reed DR, et al. Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. Cancer. 2019;125(15):2610-2620. doi:10.1002/cncr.32117
Grignani G, Le Cesne A, Martín-Broto J. Trabectedin as second-line treatment in advanced soft tissue sarcoma: quality of life and safety outcomes. Future Oncol. 2022;18(30s):13-22. doi:10.2217/fon-2022-0518
van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379(9829):1879-1886. doi:10.1016/S0140-6736(12)60651-5
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Soft Tissue Sarcoma, Version 2.2023; 2023.
Schmoll HJ, Lindner LH, Reichardt P, et al. Efficacy of pazopanib with or without gemcitabine in patients with anthracycline- and/or ifosfamide-refractory soft tissue sarcoma: final results of the PAPAGEMO phase 2 randomized clinical trial. JAMA Oncol. 2021;7(2):255-262. doi:10.1001/jamaoncol.2020.6564
Schöffski P, Toulmonde M, Estival A, et al. Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-1506-STBSG “ANITA”. Eur J Cancer. 2021;152:26-40. doi:10.1016/j.ejca.2021.04.015
Chen TW-W, Hsu CL, Hong RL, et al. A single-arm phase Ib/II study of lenvatinib plus eribulin in advanced liposarcoma and leiomyosarcoma. Clin Cancer Res. 2022;28(23):5058-5065. doi:10.1158/1078-0432.CCR-22-2092
Martin-Broto J, Hindi N, Grignani G, et al. Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial. J Immunother Cancer. 2020;8(2):e001561. doi:10.1136/jitc-2020-001561
Italiano A, Soria JC, Toulmonde M, et al. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. Lancet Oncol. 2018;19(5):649-659. doi:10.1016/S1470-2045(18)30145-1
Gounder M, Schöffski P, Jones RL, et al. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. Lancet Oncol. 2020;21(11):1423-1432. doi:10.1016/S1470-2045(20)30451-4
Gounder MM, Zer A, Tap WD, et al. Phase IB study of selinexor, a first-in-class inhibitor of nuclear export, in patients with advanced refractory bone or soft tissue sarcoma. J Clin Oncol. 2016;34(26):3166-3174. doi:10.1200/JCO.2016.67.6346
Gounder MM, Razak AA, Somaiah N, et al. Selinexor in advanced, metastatic dedifferentiated liposarcoma: a multinational, randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2022;40(22):2479-2490. doi:10.1200/JCO.21.01829
Konopleva M, Martinelli G, Daver N, et al. MDM2 inhibition: an important step forward in cancer therapy. Leukemia. 2020;34(11):2858-2874. doi:10.1038/s41375-020-0949-z
Gounder MM, Bauer TM, Schwartz GK, et al. A first-in-human phase I study of milademetan, an MDM2 inhibitor, in patients with advanced liposarcoma, solid tumors, or lymphomas. J Clin Oncol. 2023;41(9):1714-1724. doi:10.1200/JCO.22.01285
Tap WD, Gelderblom H, Palmerini E, et al. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. Lancet. 2019;394(10197):478-487. doi:10.1016/S0140-6736(19)30764-0
Palmerini E, Longhi A, Donati DM, Staals EL. Pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor: safety and efficacy. Expert Rev Anticancer Ther. 2020;20(6):441-445. doi:10.1080/14737140.2020.1757441
Tap W. ENLIVEN study: pexidartinib for tenosynovial giant cell tumor (TGCT). Future Oncol. 2020;16(25):1875-1878. doi:10.2217/fon-2020-0307
Italiano A, Bessede A, Pulido M, et al. Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort. Nature Med. 2022;28(6):1199-1206. doi:10.1038/s41591-022-01821-3
Blay JY, Chevret S, Le Cesne A, et al. Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial. Lancet Oncol. 2023;24(8):892-902. doi:10.1016/S1470-2045(23)00282-6
D'Angelo SP, Mahoney MR, Van Tine BA, et al. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol. 2018;19(3):416-426. doi:10.1016/S1470-2045(18)30006-8
Serritella AV, Shenoy NK. Nivolumab plus ipilimumab vs nivolumab alone in advanced cancers other than melanoma: a meta-analysis. JAMA Oncol. 2023;9(10):1441-1446. doi:10.1001/jamaoncol.2023.3295
Rosenbaum E, Seier K, Bradic M, et al. Immune-related adverse events after immune checkpoint blockade-based therapy are associated with improved survival in advanced sarcomas. Cancer Res Commun. 2023;3(10):2118-2125. doi:10.1158/2767-9764.CRC-22-0140
Long AH, Highfill SL, Cui Y, et al. Reduction of MDSCs with all-trans retinoic acid improves CAR therapy efficacy for sarcomas. Cancer Immunol Res. 2016;4(10):869-880. doi:10.1158/2326-6066.CIR-15-0230
Terry RL, Meyran D, Fleuren EDG, et al. Chimeric antigen receptor T cell therapy and the immunosuppressive tumor microenvironment in pediatric sarcoma. Cancers. 2021;13(18):4704. doi:10.3390/cancers13184704
Ahmed N, Brawley VS, Hegde M, et al. Human epidermal growth factor receptor 2 (HER2) -specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma. J Clin Oncol. 2015;33(15):1688-1696. doi:10.1200/JCO.2014.58.0225
Ramachandran I, Lowther DE, Dryer-Minnerly R, et al. Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma. J Immunother Cancer. 2019;7(1):276. doi:10.1186/s40425-019-0762-2
D'Angelo SP, Melchiori L, Merchant MS, et al. Antitumor activity associated with prolonged persistence of adoptively transferred NY-ESO-1 c259T cells in synovial sarcoma. Cancer Discov. 2018;8(8):944-957. doi:10.1158/2159-8290.CD-17-1417
Tawbi HA, Burgess M, Bolejack V, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017;18(11):1493-1501. doi:10.1016/S1470-2045(17)30624-1
Merchant MS, Bernstein D, Amoako M, et al. Adjuvant immunotherapy to improve outcome in high-risk pediatric sarcomas. Clin Cancer Res. 2016;22(13):3182-3191. doi:10.1158/1078-0432.CCR-15-2550
Miwa S, Nishida H, Tanzawa Y, et al. Phase 1/2 study of immunotherapy with dendritic cells pulsed with autologous tumor lysate in patients with refractory bone and soft tissue sarcoma. Cancer. 2017;123(9):1576-1584. doi:10.1002/cncr.30606
Somaiah N, Chawla SP, Block MS, et al. A phase 1b study evaluating the safety, tolerability, and immunogenicity of CMB305, a lentiviral-based prime-boost vaccine regimen, in patients with locally advanced, relapsed, or metastatic cancer expressing NY-ESO-1. Oncoimmunology. 2020;9(1):1847846. doi:10.1080/2162402X.2020.1847846
Kelly CM, Antonescu CR, Bowler T, et al. Objective response rate among patients with locally advanced or metastatic sarcoma treated with talimogene laherparepvec in combination with pembrolizumab: a phase 2 clinical trial. JAMA Oncol. 2020;6(3):402-408. doi:10.1001/jamaoncol.2019.6152
D'Angelo SP, Shoushtari AN, Agaram NP, et al. Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Hum Pathol. 2015;46(3):357-365. doi:10.1016/j.humpath.2014.11.001
Kim JR, Moon YJ, Kwon KS, et al. Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas. PLoS One. 2013;8(12):e82870. doi:10.1371/journal.pone.0082870
Maes D, McMullan C, Ford SJ, Wilson R, Oppong R, Aiyegbusi OL. Experiences of patients and their relatives of postoperative radiological surveillance and surveillance intensity following primary resection of a soft tissue sarcoma and its impact on their quality of life: a systematic review protocol. BMJ Open. 2023;13(5):e070327. doi:10.1136/bmjopen-2022-070327
Schneider P, Giglio V, Ghanem D, et al. Willingness of patients with sarcoma to participate in cancer surveillance research: a cross-sectional patient survey. BMJ Open. 2021;11(2):e042742. doi:10.1136/bmjopen-2020-042742
SAFETY Investigators. The surveillance after extremity tumor surgery (SAFETY) trial: protocol for a pilot study to determine the feasibility of a multi-centre randomised controlled trial. BMJ Open. 2019;9(9):e029054. doi:10.1136/bmjopen-2019-029054
Hampras SS, Moysich KB, Marimuthu SP, Ravi V, Jayaprakash V. Socioeconomic factors and the risk for sarcoma. Eur J Cancer Prev. 2014;23(6):560-565. doi:10.1097/CEJ.0000000000000004
Diessner BJ, Weigel BJ, Murugan P, Zhang L, Poynter JN, Spector LG. Associations of socioeconomic status, public vs private insurance, and race/ethnicity with metastatic sarcoma at diagnosis. JAMA Netw Open. 2020;3(8):e2011087. doi:10.1001/jamanetworkopen.2020.11087
Richardson SM, Wurtz LD, Collier CD. Ninety percent or greater tumor necrosis is associated with survival and social determinants of health in patients with osteosarcoma in The National Cancer Database. Clin Orthop Relat Res. 2023;481(3):512-522. doi:10.1097/CORR.0000000000002380
Wang JC, Liu KC, Gettleman BS, et al. Medicare advantage in soft tissue sarcoma may be associated with worse patient outcomes. J Clin Med. 2023;12(15):5122. doi:10.3390/jcm12155122
Dilday JC, Nelson DW, Fischer TD, Goldfarb M. Disparities in amputation rates for non-metastatic extremity soft tissue sarcomas and the impact on survival. Ann Surg Oncol. 2021;28(1):576-584. doi:10.1245/s10434-020-08586-4
Jain V, Venigalla S, Sebro RA, et al. Association of health insurance status with presentation, treatment and outcomes in soft tissue sarcoma. Cancer Med. 2019;8(14):6295-6304. doi:10.1002/cam4.2441
Alcindor T, Dumitra S, Albritton K, Thomas DM. Disparities in cancer care: the example of sarcoma-in search of solutions for a global issue. Am Soc Clin Oncol Educ Book. 2021;41:405-411. doi:10.1200/EDBK_320463
Fayet Y, Tétreau R, Honoré C, et al. Determinants of the access to remote specialised services provided by national sarcoma reference centres. BMC Cancer. 2021;21(1):631. doi:10.1186/s12885-021-08393-4
Pak LM, Kwon NK, Baldini EH, et al. Racial differences in extremity soft tissue sarcoma treatment in a universally insured population. J Surg Res. 2020;250:125-134. doi:10.1016/j.jss.2020.01.001
Lazarides AL, Visgauss JD, Nussbaum DP, et al. Race is an independent predictor of survival in patients with soft tissue sarcoma of the extremities. BMC Cancer. 2018;18(1):488. doi:10.1186/s12885-018-4397-3
Braswell AC, Jiminez V, Montgomery KB, McLeod MC, Broman KK, Eulo V. Racial and ethnic variation in presentation and outcomes of high-grade soft tissue sarcoma at a southeastern United States comprehensive cancer center. Am J Surg. 2023;S0002-9610(23):00516. doi:10.1016/j.amjsurg.2023.10.009
Alamanda VK, Song Y, Schwartz HS, Holt GE. Racial disparities in extremity soft-tissue sarcoma outcomes: a nationwide analysis. Am J Clin Oncol. 2015;38(6):595-599. doi:10.1097/COC.0000000000000004
Patel SJ, Pappoppula L, Guddati AK. Analysis of trends in race and gender disparities in incidence-based mortality in patients diagnosed with soft tissue sarcomas from 2000 to 2016. Int J Gen Med. 2021;14:3787-3791. doi:10.2147/IJGM.S296309
Sasi A, Ganguly S, Biswas B, et al. Determinants and impact of diagnostic interval in bone sarcomas: a retrospective cohort study. Pediatr Blood Cancer. 2023;70(3):e30135. doi:10.1002/pbc.30135
Curtis GL, Lawrenz JM, George J, et al. Adult soft tissue sarcoma and time to treatment initiation: an analysis of The National Cancer Database. J Surg Oncol. 2018;117(8):1776-1785. doi:10.1002/jso.25095
Seldon C, Shrivastava G, Al-Awady A, et al. Variation in management of extremity soft-tissue sarcoma in younger vs older adults. JAMA Netw Open. 2021;4(8):e2120951. doi:10.1001/jamanetworkopen.2021.20951
Hartley LJ, AlAqeel M, Kurisunkal VJ, Evans S. Outcomes of soft-tissue sarcoma in nonagenarians. Bone Joint J. 2022;104-B(1):177-182. doi:10.1302/0301-620X.104B1.BJJ-2021-0761.R1
Houdek MT, Watts CD, Wyles CC, Rose PS, Taunton MJ, Sim FH. Functional and oncologic outcome of cemented endoprosthesis for malignant proximal femoral tumors. J Surg Oncol. 2016;114(4):501-506. doi:10.1002/jso.24339
Andrews CC, Siegel G, Smith S. Rehabilitation to improve the function and quality of life of soft tissue and bony sarcoma patients. Patient Relat Outcome Meas. 2019;10:417-425. doi:10.2147/PROM.S130183
Ardakani AHG, Woollard A, Ware H, Gikas P. Soft tissue sarcoma: recognizing a rare disease. Cleve Clin J Med. 2022;89(2):73-80. doi:10.3949/ccjm.89a.21078